Ahmad Al-Homsi, MD
Hematology & Oncology · Baltimore, MDNPI 1104808047
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,145 of the $18,032 with a category attached, or 95.1%. 6 manufacturers reported payments, led by Daiichi Sankyo Inc. at 41.0% of the total. Reporting peaked in 2019 at $7,386 and has fallen 97.0% since, to $222 in 2025.
Across 12 payments — averaging $1502.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$7K
- E.r. Squibb & Sons, L.L.C.$7K
- Incyte Corporation$3K
- National Marrow Donor Program$222
- Jazz Pharmaceuticals Inc.$88
- Pharmacyclics LLC, An Abbvie Company$39
Across 1 payment — averaging $38,966 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$39K
What the payments were for
- Consulting fees$17,14595%
- Travel & lodging$2722%
- Food & beverage$6153%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 3 | $7,386 |
| E.r. Squibb & Sons, L.L.C. | 2 | $7,140 |
| Incyte Corporation | 3 | $3,157 |
| National Marrow Donor Program | 1 | $222 |
| Jazz Pharmaceuticals Inc. | 1 | $88 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JAKAFI$3,157
How this compares
$18,032 in reported general payments places this provider in the 80th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Baltimore
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
- Huzefa BahrainBaltimore$102K
- Tania JainBaltimore$95K
- Josephine FelicianoBaltimore$72K
- Abhijeet KumarBaltimore$66K
- Michael AuerbachBaltimore$64K
- Suman RaoBaltimore$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.